Risk Factors for Recurrent VTE
| Characteristic . | Recurrent VTE risk . | Patient population . | Reference . |
|---|---|---|---|
| Cancer stage | |||
| TNM stage 1 and 2 | HR, 1.9 (0.8-4.2) | First VTE with or without cancer | 3 |
| TNM stage 3 | HR, 5.3 (2.5-10.9) | ||
| TNM stage 4 | HR, 4.6 (2.3-9.0) | ||
| Metastatic vs localized disease | RR, 1.36 (1.06-1.74) | Active cancer and acute VTE | 49 |
| Stage IV pancreatic | HR, 6.38 (2.69-15.13) | Active cancer-associated incident VTE | 50 |
| Stage IV cancer (non-pancreatic) | HR, 2.85 (1.74-4.67) | ||
| Cancer stage progression | HR, 2.14 (1.30-3.52) | ||
| Cancer site | |||
| Lung | HR, 6.9 (3.0-15.9) | First VTE with or without cancer | 3 |
| Gastrointestinal | HR, 5.1 (2.3-11.3) | ||
| Genitourinary | HR, 3.7 (1.7-8.0) | ||
| Hepatobiliary | HR, 2.9 (1.2-7.0) | Active cancer and acute VTE | 51 |
| Brain cancer | HR, 4.57 (2.07-10.09) | Active cancer-associated incident VTE | 50 |
| Myeloproliferative disorder or myelodysplastic disorder | HR, 3.49 (1.59-7.68) | ||
| Ovarian cancer | HR, 3.22 (1.57-6.59) | ||
| Lung cancer | HR, 2.73 (1.63-4.55) | ||
| Other patient characteristics | |||
| Elevated tissue factor level (>64.6 pg/mL) | aHR, 3.4 (2.1-5.5) | Active cancer and acute VTE | 51 |
| Venous compression | HR, 2.96 (1.8-4.9) | ||
| Neurologic disease with leg paresis | HR, 2.38 (1.14-4.97) | Active cancer-associated incident VTE | 50 |
| Cancer diagnosis within 3 mo of VTE | OR, 2.4 (1.5-3.6) for DVT; OR, 2.0 (1.2-3.1) for PE | Active cancer and acute VTE | 52 |
| Patient age <65 y | OR, 1.6 (1.0-2.4) for DVT; OR, 3.0 (1.9-4.9) for PE | ||
| Clinically overt PE upon presentation | OR, 1.9 (1.2-3.2) for PE | ||
| Characteristic . | Recurrent VTE risk . | Patient population . | Reference . |
|---|---|---|---|
| Cancer stage | |||
| TNM stage 1 and 2 | HR, 1.9 (0.8-4.2) | First VTE with or without cancer | 3 |
| TNM stage 3 | HR, 5.3 (2.5-10.9) | ||
| TNM stage 4 | HR, 4.6 (2.3-9.0) | ||
| Metastatic vs localized disease | RR, 1.36 (1.06-1.74) | Active cancer and acute VTE | 49 |
| Stage IV pancreatic | HR, 6.38 (2.69-15.13) | Active cancer-associated incident VTE | 50 |
| Stage IV cancer (non-pancreatic) | HR, 2.85 (1.74-4.67) | ||
| Cancer stage progression | HR, 2.14 (1.30-3.52) | ||
| Cancer site | |||
| Lung | HR, 6.9 (3.0-15.9) | First VTE with or without cancer | 3 |
| Gastrointestinal | HR, 5.1 (2.3-11.3) | ||
| Genitourinary | HR, 3.7 (1.7-8.0) | ||
| Hepatobiliary | HR, 2.9 (1.2-7.0) | Active cancer and acute VTE | 51 |
| Brain cancer | HR, 4.57 (2.07-10.09) | Active cancer-associated incident VTE | 50 |
| Myeloproliferative disorder or myelodysplastic disorder | HR, 3.49 (1.59-7.68) | ||
| Ovarian cancer | HR, 3.22 (1.57-6.59) | ||
| Lung cancer | HR, 2.73 (1.63-4.55) | ||
| Other patient characteristics | |||
| Elevated tissue factor level (>64.6 pg/mL) | aHR, 3.4 (2.1-5.5) | Active cancer and acute VTE | 51 |
| Venous compression | HR, 2.96 (1.8-4.9) | ||
| Neurologic disease with leg paresis | HR, 2.38 (1.14-4.97) | Active cancer-associated incident VTE | 50 |
| Cancer diagnosis within 3 mo of VTE | OR, 2.4 (1.5-3.6) for DVT; OR, 2.0 (1.2-3.1) for PE | Active cancer and acute VTE | 52 |
| Patient age <65 y | OR, 1.6 (1.0-2.4) for DVT; OR, 3.0 (1.9-4.9) for PE | ||
| Clinically overt PE upon presentation | OR, 1.9 (1.2-3.2) for PE | ||
aHR, adjusted hazard ratio; TNM, tumor-node-metastasis.